Menu Search
Equities

Hikma Pharmaceuticals PLC

HIK:LSE

Hikma Pharmaceuticals PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,690.00
  • Today's Change-68.50 / -3.90%
  • Shares traded1.02m
  • 1 Year change-32.13%
  • Beta0.1997
Data delayed at least 20 minutes, as of May 24 2022 16:45 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Forecasts data is unavailable for this security.

Consensus recommendation

  • 17-Jun-21
  • 17-Mar-22
  • 14-Apr-22
  • 19-May-22
  • 24-May-22
Select bar for recommendation details.
Recommendations24-May-22
Buy7
Outperform3
Hold2
Underperform0
Sell0

Share price forecast

The 10 analysts offering 12 month price targets for Hikma Pharmaceuticals Plc have a median target of 2,645.75, with a high estimate of 2,900.71 and a low estimate of 2,057.98. The median estimate represents a 56.55% increase from the last price of 1,690.00.
High65.0%2,900.71
Med50.5%2,645.75
Low17.0%2,057.98

Dividends

In 2021, Hikma Pharmaceuticals PLC reported a dividend of 0.55 USD, which represents a 8.70% increase over last year. The 11 analysts covering the company expect dividends of 0.56 USD for the upcoming fiscal year, an increase of 0.99%.
Div growth (TTM)8.70%
More ▼

Earnings history & estimates

Hikma Pharmaceuticals Plc reported annual 2021 earnings of 1.93 per share on Feb 24, 2022.
Average growth rate+16.71%
More ▼

Revenue history & estimates

Hikma Pharmaceuticals PLC had revenues for the full year 2021 of 2.55bn. This was 9.06% above the prior year's results.
Average growth rate+7.17%
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.